Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Phages and cancer immunity Gut bacteria are involved in the education of T cell immune responses, and the intestinal ecosystem influences anticancer immunity. Fluckiger et al. report microbial antigens that might cross-react with antigens associated with tumor cells. They found that a type of intestinal bacteria called enterococci harbor a bacteriophage that modulates immune responses. In mouse models, administration of enterococci containing the bacteriophage boosted T cell responses after treatment with chemotherapy or programmed cell death protein 1 (PD-1) blockade. In humans, the presence of the bacteriophage was associated with improved survival after PD-1 immunotherapy. A fraction of human T cells specific for naturally processed melanoma epitopes appeared to be able to recognize microbial peptides. This “molecular mimicry” may represent cross-reactivity between tumors and microbial antigens. Science , this issue p. 936
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, bacteriophages as therapeutic strategies could modulate the gut microbiota, immunity, and TME [70, 164–166].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [70]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an E. hirae strain carrying a prophage from the Siphoviridae family translocates to mLNs and the spleen”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“boosts the T cell-dependent efficacy of cyclophosphamide or PD-1 blockade”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“molecular mimicry between microbial and tumor-associated antigens, resulting in cross-reactive T cell responses 55”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, the gut microbiome’s vast antigen reservoir may facilitate cross-reactivity between bacterial and tumor antigens, thereby enhancing antitumor immune responses (Fluckiger et al., 2020; Naghavian et al., 2023).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Fluckiger et al., 2020
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing
Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., Lesin, V. M., Nikolenko, S. I., Pham, S., Prjibelski, A. D., et al. (2012) · Journal of Computational Biology · doi:10.1089/cmb.2012.0021 · Cited by 25,987
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
OrthoMCL: Identification of Ortholog Groups for Eukaryotic Genomes
Li, L., Stoeckert, C. J., & Roos, D. S. (2003) · Genome Research · doi:10.1101/gr.1224503 · Cited by 5,707
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Cited by
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Self-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Role and Mechanism of Gut Microbiota in Human Disease
Chen, Y., Zhou, J., & Wang, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.625913 · Cited by 627
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
Self-citationLópez-Otín, C., & Kroemer, G. (2021) · Cell · doi:10.1016/j.cell.2020.11.034 · Cited by 499
Self-citationRole of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 442
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Self-citationGut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Cancer vaccines: Building a bridge over troubled waters
Sellars, M. C., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 318
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00554-7 · Cited by 289
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Inflammation: the incubator of the tumor microenvironment
Denk, D., & Greten, F. R. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.07.002 · Cited by 273
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Tisza, M. J., & Buck, C. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023202118 · Cited by 273
A pan-cancer analysis of the microbiome in metastatic cancer
Battaglia, T. W., Mimpen, I. L., Traets, J. J. H., van Hoeck, A., Zeverijn, L. J., Geurts, B. S., de Wit, G. F., Noë, M., Hofland, I., Vos, J. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.021 · Cited by 218
Exploiting bacteria for cancer immunotherapy
Kwon, S.-Y., Thi-Thu Ngo, H., Son, J., Hong, Y., & Min, J.-J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00908-9 · Cited by 201
Wang, M., Rousseau, B., Qiu, K., Huang, G., Zhang, Y., Su, H., Le Bihan-Benjamin, C., Khati, I., Artz, O., Foote, M. B., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01957-8 · Cited by 211
Mutualistic interplay between bacteriophages and bacteria in the human gut
Shkoporov, A. N., Turkington, C. J., & Hill, C. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00755-4 · Cited by 185
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Bacteriophages and the Immune System
Popescu, M., Van Belleghem, J. D., Khosravi, A., & Bollyky, P. L. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-074551 · Cited by 178
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 198
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Self-citationMicrobial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
Grajeda-Iglesias, C., Durand, S., Daillère, R., Iribarren, K., Lemaitre, F., Derosa, L., Aprahamian, F., Bossut, N., Nirmalathasan, N., Madeo, F., et al. (2021) · Aging · doi:10.18632/aging.202739 · Cited by 161
Self-citationWu, H., Leng, X., Liu, Q., Mao, T., Jiang, T., Liu, Y., Li, F., Cao, C., Fan, J., Chen, L., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2593 · Cited by 160
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Expanding known viral diversity in the healthy infant gut
Shah, S. A., Deng, L., Thorsen, J., Pedersen, A. G., Dion, M. B., Castro-Mejía, J. L., Silins, R., Romme, F. O., Sausset, R., Jessen, L. E., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01345-7 · Cited by 160
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citationMa, J., Huang, L., Hu, D., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02128-w · Cited by 152
The landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 147
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
“Finally, in some instances, specific endogenous gut bacteria may harbor antigens that cross-react with tumor antigens/neoantigens and may increase T cell mediated anti-cancer immune responses via molecular mimicry (23).”
Podlacha, M., Grabowski, Ł., Kosznik-Kawśnicka, K., Zdrojewska, K., Stasiłojć, M., Węgrzyn, G., & Węgrzyn, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168937 · Cited by 124
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 142
Intestinal phages interact with bacteria and are involved in human diseases
Shuwen, H., & Kefeng, D. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2113717 · Cited by 124
“Furthermore, the expression of the mimic carcinogenic peptide PSMB4 in phage TMP1 can effectively inhibit the growth of tumors to improve the effect of immunotherapy.(91,92) Murgas P et al.”
BackgroundThe cancer-immune dialogue in the context of stress
Ma, Y., & Kroemer, G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00949-8 · Cited by 131
Self-citationGao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Genome binning of viral entities from bulk metagenomics data
Johansen, J., Plichta, D. R., Nissen, J. N., Jespersen, M. L., Shah, S. A., Deng, L., Stokholm, J., Bisgaard, H. F., Nielsen, D. S., Sørensen, S. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28581-5 · Cited by 121
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Lawler, M., Davies, L., Oberst, S., Oliver, K. R., Eggermont, A. M. M., Schmutz, A., Vecchia, C. L., Allemani, C., Lievens, Y. N., Naredi, P. L. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00540-x · Cited by 130
Self-citationImmunogenicity of bacteriophages
Champagne-Jorgensen, K., Luong, T., Darby, T., & Roach, D. R. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.04.008 · Cited by 115
Lin, H., Yang, C., Luo, Y., Ge, M., Shen, H., Zhang, X., & Shi, J. (2022) · ACS Nano · doi:10.1021/acsnano.1c11132 · Cited by 114
Beneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 111
Self-citationAghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
Glioblastoma vaccines: past, present, and opportunities
Xiong, Z., Raphael, I., Olin, M. R., Okada, H., Li, X., & Kohanbash, G. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104963 · Cited by 108
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Hou, S., Yu, J., Li, Y., Zhao, D., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202413197 · Cited by 116
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Self-citationEngineering the gut microbiome
Bai, X., Huang, Z., Duraj‐Thatte, A., Ebert, M., Zhang, F., Burgermeister, E., Liu, X., Scott, B. M., Li, G., & Zuo, T. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00072-2 · Cited by 92
Microbiota-driven antitumour immunity mediated by dendritic cell migration
Lin, Y.-T., Fukuoka, S., Koyama, S., Motooka, D., Tourlousse, D. M., Shigeno, Y., Matsumoto, Y., Yamano, H., Murotomi, K., Tamaki, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09249-8 · Cited by 90
The Microbiome and Cancer: A Translational Science Review
Fernandez, E., Wargo, J. A., & Helmink, B. A. (2025) · JAMA · doi:10.1001/jama.2025.2191 · Cited by 95
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 81
Terrisse, S., Goubet, A.-G., Ueda, K., Thomas, A. M., Quiniou, V., Thelemaque, C., Dunsmore, G., Clave, E., Gamat-Huber, M., Yonekura, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004191 · Cited by 80
Self-citationNavigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 86
Rethinking phage-bacteria-eukaryotic relationships and their influence on human health
Wahida, A., Tang, F., & Barr, J. J. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.007 · Cited by 85
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
Zhang, H., Fu, L., Leiliang, X., Qu, C., Wu, W., Wen, R., Huang, N., He, Q., Cheng, Q., Liu, G., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12597 · Cited by 78
Feola, S., Russo, S., Ylösmäki, E. O., & Cerullo, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108103 · Cited by 72
Molecular mimicry and cancer vaccine development
Tagliamonte, M., Cavalluzzo, B., Mauriello, A., Ragone, C., Buonaguro, L., Tornesello, M. L., & Buonaguro, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01776-0 · Cited by 72
Integrating the gut microbiome and pharmacology
Verdegaal, A. A., & Goodman, A. L. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg8357 · Cited by 71
Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies
Neil, V. M., & Lee, S. W. (2025) · Cancers · doi:10.3390/cancers17091408 · Cited by 74
Tumor-Associated Microbiome: Where Do We Stand?
Oliva, M., Mulet-Margalef, N., Ochoa-de-Olza, M., Napoli, S., Mas-Lloret, J., Laquente, B., Alemany, L., Duell, E. J., Nuciforo, P. G., & Moreno, V. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031446 · Cited by 65
Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
Hou, X., Zheng, Z., Wei, J., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030745 · Cited by 66
Wang, Y., Li, Y., Lin, Y., Cao, C.-Y., Chen, D., Huang, X., Li, C., Xu, H., Lai, H., Chen, H., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02413-z · Cited by 70
Bacillus Calmette–Guérin Immunotherapy for Cancer
Cardillo, F., Bonfim, M., Sousa-Vasconcelos, P. D. S., Mengel, J., Castello-Branco, L. R. R., & Pinho, R. T. (2021) · Vaccines · doi:10.3390/vaccines9050439 · Cited by 65
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 58
Tumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 63
Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors
Xiong, X., Tian, S., Yang, P., Lebreton, F., Bao, H., Sheng, K., Yin, L., Chen, P., Zhang, J., Qi, W., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.002 · Cited by 57
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
The microbiome(s) and cancer: know thy neighbor(s)
González‐Sánchez, P., & DeNicola, G. M. (2021) · The Journal of Pathology · doi:10.1002/path.5661 · Cited by 61
Metabolic regulation in the immune response to cancer
Wu, Q., Yu, X., Li, J., Sun, S., & Tu, Y. (2021) · 癌症:英文版 · doi:10.1002/cac2.12182 · Cited by 62
Microbiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 65
Bacteriophage-Bacteria Interactions in the Gut: From Invertebrates to Mammals
Kirsch, J. M., Brzozowski, R., Faith, D. R., Round, J. L., Secor, P. R., & Duerkop, B. A. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-101238 · Cited by 55
Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54
Self-citationHow microbiota improve immunotherapy
Ansaldo, E., & Belkaid, Y. (2021) · Science · doi:10.1126/science.abl3656 · Cited by 54
Potential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 55
Liu, X., Lu, B., Tang, H. T., Jia, X., Zhou, Q., Zeng, Y., Gao, X., Chen, M., Xu, Y., Wang, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105427 · Cited by 58
The Emerging Biotherapeutic Agent: Akkermansia
Kalia, V. C., Gong, C., Shanmugam, R., Lin, H. M., Zhang, L., & Lee, J.-K. (2021) · Indian Journal of Microbiology · doi:10.1007/s12088-021-00993-9 · Cited by 56
Bodywide ecological interventions on cancer
Kroemer, G., McQuade, J. L., Mérad, M., André, F., & Zitvogel, L. (2023) · Nature Medicine · doi:10.1038/s41591-022-02193-4 · Cited by 57
Self-citationCAR-T therapy dilemma and innovative design strategies for next generation
Wang, Z., Li, P., Zeng, X., Guo, J., Zhang, C., Fan, Z., Wang, Z., Zhu, P., & Chen, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07454-x · Cited by 57
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
Microbiome in cancer progression and therapy
Andreeva, N., Gabbasova, R. R., & Grivennikov, S. I. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.001 · Cited by 49
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?
Guo, H., Zhao, L., Zhu, J., Chen, P., Wang, H., Jiang, M., Liu, X., Sun, H., Zhao, W., Zheng, Z., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.025 · Cited by 49
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
Liu, N., Chen, L., Yan, M., Tao, Q., Wu, J., Chen, J., Chen, X., Zhang, W., & Peng, C. (2023) · Research · doi:10.34133/research.0127 · Cited by 41
The intratumoral microbiota: friend or foe?
Ferrari, V., & Rescigno, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.03.005 · Cited by 45
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 48
Metadata
- Authors
- Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., Lemaitre, F., Ferrere, G., Derosa, L., Duong, C. P. M., Messaoudene, M., Gagné, A., Joubert, P., De Sordi, L., Debarbieux, L., Simon, S., Scarlata, C.-M., Ayyoub, M., Palermo, B., Facciolo, F., Boidot, R., Wheeler, R., Boneca, I. G., Sztupinszki, Z., Papp, K., Csabai, I., Pasolli, E., Segata, N., Lopez-Otin, C., Szallasi, Z., Andre, F., Iebba, V., Quiniou, V., Klatzmann, D., Boukhalil, J., Khelaifia, S., Raoult, D., Albiges, L., Escudier, B., Eggermont, A., Mami-Chouaib, F., Nistico, P., Ghiringhelli, F., Routy, B., Labarrière, N., Cattoir, V., Kroemer, G., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- Université de Bourgogne (FR)
- Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Bacteriophage, Bacterium, Host Laboratory, Institut Pasteur, F-75015 Paris, France.
- Institut Pasteur (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Centre Georges François Leclerc (FR)
- Computational Health Informatics Program (CHIP), Boston Children's Hospital, Boston, MA, USA.
- Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, Hungary.
- University of Naples Federico II (IT)
- University of Trento (IT)
- Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
- Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy, Villejuif, France.
- University of Trieste (IT)
- UMR MEPHI, Aix-Marseille Université, IRD, AP-HM, Institut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13385, Marseille cedex 05, France.
- Aix-Marseille Université (FR)
- Institut Gustave Roussy (FR)
- INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine - Univ. Paris-Sud, Université Paris-Saclay, 94805, Villejuif, France.
- Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Karolinska University Hospital (SE)
- Corresponding author
- Kroemer, Guido
- Zitvogel, Laurence
- ORCID
- Fluckiger, Aurélie
- Daillère, Romain
- Sassi, Mohamed
- Sixt, Barbara Susanne
- Liu, Peng
- Loos, Friedemann
- Richard, Corentin
- Rabu, Catherine
- Alou, Maryam Tidjani
- Goubet, Anne-Gaëlle
- Lemaitre, Fabien
- Ferrere, Gladys
- Derosa, Lisa
- Duong, Connie P. M.
- Messaoudene, Meriem
- Gagné, Andréanne
- Joubert, Philippe
- De Sordi, Luisa
- Debarbieux, Laurent
- Simon, Sylvain
- Scarlata, Clara-Maria
- Ayyoub, Maha
- Palermo, Belinda
- Facciolo, Francesco
- Boidot, Romain
- Wheeler, Richard
- Boneca, Ivo Gomperts
- Sztupinszki, Zsofia
- Papp, Krisztian
- Csabai, Istvan
- Pasolli, Edoardo
- Segata, Nicola
- Lopez-Otin, Carlos
- Szallasi, Zoltan
- Andre, Fabrice
- Iebba, Valerio
- Quiniou, Valentin
- Klatzmann, David
- Khelaifia, Saber
- Raoult, Didier
- Albiges, Laurence
- Escudier, Bernard
- Eggermont, Alexander
- Nistico, Paola
- Ghiringhelli, François
- Routy, Bertrand
- Labarrière, Nathalie
- Cattoir, Vincent
- Kroemer, Guido
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2020-08-21
- Volume
- 369
- Issue
- 6506
- Pages
- 936-942
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3081393016
- Cited by
- 396
- References
- 53
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 59 · 2023: 80 · 2022: 61 · 2021: 62 · 2020: 9
- FWCI
- 18.57
- Type
- journal article
- Language
- en
- Open access
- green
- inserm.hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-19-CE15-0029, ANR-16-RHUS-0008)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- Keywords
- bacteriophages, Enterococcus, cross-reactivity, molecular mimicry, tumor antigens, T cell response, gut microbiota, cancer immunotherapy, anti-PD-1 therapy, chemotherapy, microbial peptides, immune checkpoint inhibitors
- MeSH terms
- Gastrointestinal Microbiome, Enterococcus hirae, Animals, Antibodies, Monoclonal, Epitopes, Antigens, Neoplasm, Bacteriophages, Cross Reactions, Cyclophosphamide, Feces, H-2 Antigens, Humans, Immunotherapy, Neoplasms, Histocompatibility Antigens Class I, Viral Tail Proteins, CD8-Positive T-Lymphocytes, Antineoplastic Agents, Alkylating, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.